Although both urinary and circulating levels of NGAL have been extensively studied as (early) biomarker for AKI and CKD progression, its potential role as biomarker for pre-diagnostic CKD has only been investigated once in a small, matched case–control study [16]. This evidence concerns the gene LCN2 and acute kidney injury.